Inhibition of MMPs supports amoeboid angiogenesis hampering VEGF-targeted therapies via MLC and ERK 1/2 signaling.

Anastasia ChillàCecilia AnceschiElena FredianiFrancesca ScavoneTommaso Del RossoGiuseppe PelagioAntonio TufaroGiuseppe De PalmaMario Del RossoGabriella FibbiPaola ChiarugiAnna LaurenzanaFrancesca Margheri

Published in: Journal of translational medicine (2023)

We underline the importance to consider the amoeboid mechanism of endothelial and cancer cell invasion, probably responsible for the failure of synthetic metalloproteinase inhibitors as cancer therapy and tumor resistance to VEGF-targeted therapies, to set-up new drugs to be used in cancer therapy.

Keyphrases

cancer therapy
endothelial cells
vascular endothelial growth factor
drug delivery
papillary thyroid
signaling pathway
squamous cell
cell proliferation
drug induced